Beta-adrenergic receptor blockers are the only antianginal drug class with proven mortality benefit in the post-MI population, and they remain first-line pharmacotherapy for stable exertional angina in most contemporary guidelines.5·6 Their anti-ischemic mechanism is straightforward and physiologically coherent: by attenuating sympathetic stimulation of the heart, they reduce the two primary determinants of myocardial oxygen demand, specifically heart rate and contractility, while simultaneously prolonging diastole and thereby enhancing coronary perfusion.1 This dual supply-demand effect makes beta-blockers uniquely well positioned among antianginal agents.
Within the class, meaningful pharmacological heterogeneity exists. Cardioselectivity, intrinsic sympathomimetic activity, vasodilatory properties, lipid solubility, and half-life differ substantially across agents and carry direct clinical consequences for drug selection.9·13
Beta-1 receptors are cardiac-predominant, located in the SA node, AV node, ventricular myocardium, and juxtaglomerular cells. Stimulation produces increased heart rate (positive chronotropy), increased AV conduction velocity, increased contractility (positive inotropy), and increased renin release. Beta-1 stimulation drives the demand-side increases that precipitate exertional ischemia; beta-1 blockade is the primary anti-ischemic mechanism of this drug class.1·9 Beta-2 receptors are peripheral and pulmonary predominant, located in bronchial smooth muscle, vascular smooth muscle (peripheral and coronary), skeletal muscle, and liver. Stimulation produces bronchodilation, peripheral vasodilation (including coronary), glycogenolysis, gluconeogenesis, and hypokalemia. Beta-2 blockade causes bronchoconstriction (hazardous in asthma and chronic obstructive pulmonary disease (COPD)) and removes a coronary vasodilatory mechanism that is relevant in vasospastic angina.8 Alpha-1 receptors are located in vascular smooth muscle (peripheral and coronary). Stimulation produces vasoconstriction. Non-selective beta-blockers that block only beta receptors leave alpha-1 vasoconstriction unopposed. In coronary vasospasm, this unopposed alpha-mediated coronary vasoconstriction can precipitate or worsen spasm; this is the fundamental reason non-selective beta-blockers are contraindicated in vasospastic angina.8
Non-selective agents (blocking beta-1 and beta-2 equally) include propranolol, nadolol, timolol, carvedilol (which also blocks alpha-1), and labetalol (which also blocks alpha-1).9 Cardioselective agents (with preferential beta-1 blockade) include metoprolol, atenolol, bisoprolol, nebivolol, acebutolol, and betaxolol.9 Cardioselectivity is relative, not absolute; at high doses, cardioselective agents lose selectivity and also block beta-2 receptors. The clinical relevance is at standard therapeutic doses: cardioselective agents cause significantly less bronchoconstriction and less interference with peripheral vasodilation and glucose metabolism.8·9
Intrinsic sympathomimetic activity (ISA): some beta-blockers are partial agonists: they block beta receptors from full agonist stimulation while providing a baseline level of receptor activation. Agents with ISA include pindolol, acebutolol, and oxprenolol.9 Clinical consequences include lower resting HR reduction (less bradycardia at rest) and less reduction in resting cardiac output. ISA blunts the resting HR reduction that is therapeutically desirable in angina. No mortality benefit has been demonstrated post-MI with ISA agents; agents without ISA are preferred for all cardioprotective indications.1·9
Additional vasodilatory properties: carvedilol provides non-selective BB plus alpha-1 blockade leading to peripheral vasodilation, additional afterload reduction, and antioxidant properties, making carvedilol preferred in heart failure with reduced ejection fraction (HFrEF).4·11 Nebivolol is a highly cardioselective beta-1 blocker with endothelial nitric oxide synthase (eNOS) stimulation producing NO-mediated vasodilation, less peripheral vasoconstriction, better erectile function profile, and a favorable metabolic profile.12 Lipid solubility determines CNS penetration: lipophilic agents (propranolol, metoprolol, carvedilol) cross the blood-brain barrier (BBB) readily and carry potential for CNS adverse effects (fatigue, sleep disturbance, vivid dreams, depression) and a shorter half-life due to hepatic first-pass metabolism. Hydrophilic agents (atenolol, nadolol) are renally excreted, cause fewer CNS effects, and require dose adjustment in CKD.9
Beta-1 blockade in the SA node reduces the rate of spontaneous depolarization (phase 4 of the action potential), lowering resting and exertional HR.1·9 On the demand side, HR is the single largest determinant of myocardial oxygen consumption (MVO2). Reducing resting HR by 10-15 bpm lowers rate-pressure product (RPP) by approximately 15% before any physical activity, shifting the entire exertional demand curve downward.5·6 At peak exercise, beta-blockers prevent the sympathetically mediated surge in HR that would otherwise push the patient above their ischemic threshold. On the supply side, LV coronary perfusion occurs predominantly during diastole; systolic compressive forces preclude meaningful subendocardial perfusion during systole. Tachycardia disproportionately shortens diastole relative to systole. Beta-blocker-induced bradycardia prolongs absolute diastolic time per cycle AND per minute, increasing coronary filling time.1 The target resting HR is 55-60 bpm in stable angina management.5·6 Below 50 bpm, the risk of symptomatic bradycardia, fatigue, and reduced exercise tolerance outweighs the anti-ischemic benefit.
Beta-1 blockade in the ventricular myocardium reduces the force of contraction (negative inotropy) via reduced cAMP production (inhibition of adenylyl cyclase), reduced PKA activity, reduced phosphorylation of L-type Ca2+ channels and ryanodine receptors, reduced intracellular Ca2+ transient, and reduced cross-bridge cycling.9 Reduced contractility directly reduces ATP consumption per cardiac cycle. In stable HFrEF, carvedilol, metoprolol succinate, and bisoprolol improve survival because the negative inotropic effect is offset by beneficial neurohormonal blockade over time.2·3·11 Acute initiation in decompensated HF risks further hemodynamic deterioration. In angina with HFrEF, beta-blockers are PREFERRED as they address both pathologies simultaneously.2·3
When nitrates or DHP-CCBs reduce blood pressure, the baroreceptor reflex drives sympathetic activation leading to reflex tachycardia and increased contractility that partially negates their anti-ischemic benefit. Beta-blockers completely block this reflex: HR cannot rise despite sympathetic activation, and the anti-ischemic benefit of vasodilation is fully preserved.5·6 This is the principal hemodynamic rationale for the beta-blocker + nitrate and beta-blocker + dihydropyridine calcium channel blocker (DHP-CCB) combinations.
Beta-blocker-induced reduction in cardiac output leads to a modest reduction in systolic BP, further reducing systolic wall stress (Laplace's Law). This afterload reduction is secondary and modest compared with CCBs or nitrates, but contributes to the overall decrease in MVO2.5
Selectivity: cardioselective (beta-1 preferential). ISA: none. Lipid solubility: moderate-high (some CNS penetration). Half-life: 12-24 hours allowing once-daily dosing with sustained plasma levels. Metabolism: hepatic (CYP2D6) with significant first-pass effect. Bioavailability: ~50% (ER formulation provides a smoother plasma profile). Angina dosing: 25-200 mg once daily.2 Clinical advantages include once-daily dosing improving adherence and proven mortality benefit post-MI and in HFrEF (MERIT-HF trial).2 It is preferred over tartrate formulation (metoprolol tartrate is immediate-release with plasma level fluctuations). CYP2D6 poor metabolizers (~7-10% of Caucasians) have significantly higher plasma concentrations at standard doses; consider lower starting doses if bradycardia or hypotension occurs.9
Pharmacokinetic detail and dose adjustment: Metoprolol undergoes extensive first-pass hepatic metabolism via CYP2D6, resulting in bioavailability of approximately 38-50% after oral administration.9 CYP2D6 poor metabolizers (a genetically determined subgroup comprising approximately 7-10% of populations of European descent and less commonly in East Asian populations) lack functional CYP2D6 and achieve plasma metoprolol concentrations three to five times higher than extensive metabolizers at the same dose.9 This produces more pronounced bradycardia and hypotension and increases the risk of adverse effects. Conversely, strong CYP2D6 inhibitors, including fluoxetine, paroxetine, bupropion, and quinidine, effectively convert extensive metabolizers to poor metabolizer status pharmacokinetically, substantially raising metoprolol plasma levels; dose reduction or closer HR monitoring is warranted when these combinations are used.9 Renal impairment does not require dose adjustment for metoprolol because its elimination is predominantly hepatic and the inactive glucuronide metabolites that are renally cleared have no pharmacological activity. Metoprolol is therefore preferred over atenolol in patients with significant chronic kidney disease who require a cardioselective beta-blocker for angina.9 Hepatic impairment reduces first-pass metabolism and increases bioavailability; in severe hepatic disease (Child-Pugh C), metoprolol doses should be initiated at the lower end of the range with careful titration.9
Selectivity: cardioselective (beta-1 preferential). ISA: none. Lipid solubility: low (hydrophilic). Half-life: 6-9 hours (twice-daily dosing usually needed for full 24-hour angina coverage). Elimination: renal; dose reduction required in CKD (eGFR <35 mL/min/1.73m2). Angina dosing: 25-100 mg once or twice daily.9 Advantages include low CNS penetration leading to fewer sleep disturbances. Limitations include weaker post-MI mortality evidence than metoprolol succinate in some analyses, and renal dose adjustment complexity in CKD patients; switch to hepatically cleared agents (metoprolol or bisoprolol) in advanced CKD.9
Pharmacokinetic detail and dose adjustment: Atenolol is unique among commonly used cardioselective beta-blockers in being predominantly renally eliminated: approximately 85-100% of absorbed drug is excreted unchanged in the urine, with minimal hepatic metabolism.9 This renders atenolol highly dependent on renal function for clearance. In patients with eGFR 15-35 mL/min/1.73m2, the dosing interval should be extended to every 48 hours or the dose halved.9 In patients with eGFR below 15 mL/min/1.73m2 or on hemodialysis, atenolol is generally avoided as it accumulates substantially and is only partially removed by hemodialysis. Because atenolol does not rely on CYP2D6, it lacks the pharmacokinetic drug interactions that affect metoprolol and nebivolol, making it predictable in patients not requiring renal dose adjustment.9 However, in the context of a patient with angina who also has advancing chronic kidney disease, switching from atenolol to bisoprolol or metoprolol succinate is preferable because both have mixed or predominant hepatic clearance and do not require renal dose reduction.9 Atenolol crosses the blood-brain barrier minimally, explaining its lower incidence of CNS adverse effects (sleep disturbance, vivid dreams, fatigue) compared with lipophilic agents.9
Selectivity: highest cardioselectivity in class (highest beta-1/beta-2 selectivity ratio). ISA: none. Lipid solubility: intermediate. Half-life: 9-12 hours (once-daily dosing adequate). Elimination: 50% hepatic, 50% renal. Angina dosing: 5-20 mg once daily. HFrEF dosing: 1.25 mg start; target 10 mg/day (CIBIS-II trial).3 Clinical advantages include highest cardioselectivity making it preferred in patients with mild-moderate COPD or asthma where a beta-blocker is still deemed necessary;8 once-daily dosing; predictable pharmacokinetics; proven HFrEF survival benefit (CIBIS-II);3 and preference in elderly patients with multiple comorbidities.
Pharmacokinetic detail and dose adjustment: Bisoprolol has a dual elimination pathway: approximately 50% is metabolized hepatically (via CYP3A4 (cytochrome P450 3A4) rather than CYP2D6, distinguishing it from metoprolol, carvedilol, and nebivolol) to inactive metabolites, and 50% is excreted unchanged in the urine.9 This dual pathway gives bisoprolol an important practical advantage: moderate impairment of either organ alone does not produce the degree of accumulation seen with single-elimination-pathway drugs. In patients with eGFR 20-40 mL/min/1.73m2, dose reduction to a maximum of 10 mg once daily is generally recommended; in severe renal impairment (eGFR below 20 mL/min/1.73m2), careful dose reduction to 2.5-5 mg with close monitoring is advised.9 In moderate hepatic impairment (Child-Pugh B), the maximum recommended dose is 10 mg daily; severe hepatic impairment warrants starting at 2.5 mg with careful uptitration. Because bisoprolol uses CYP3A4 rather than CYP2D6, it is not subject to the pharmacokinetic interactions associated with CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion), making it a preferred agent in patients requiring concurrent use of these medications.9 Its intermediate lipophilicity results in moderate CNS penetration, producing fewer CNS adverse effects than propranolol but more than atenolol.9
Selectivity: non-selective beta-blocker (beta-1 and beta-2) plus alpha-1 blocker. ISA: none. Vasodilation: yes, via alpha-1 blockade and antioxidant properties. Lipid solubility: high. Half-life: 6-10 hours (twice-daily dosing). Metabolism: hepatic (CYP2D6, CYP2C9 (cytochrome P450 2C9)) with significant first-pass effect. Angina dosing: 6.25-25 mg twice daily. HFrEF dosing: 3.125 mg twice daily starting dose; target 25-50 mg twice daily.4·11 Clinical advantages in angina include alpha-1 blockade providing additional afterload reduction, useful in HFrEF plus angina,4 and post-MI with LV dysfunction: CAPRICORN showed reduced all-cause and CV mortality.11 Limitations include non-selectivity (avoid in significant bronchospastic disease and vasospastic angina), alpha-1 blockade causing orthostatic hypotension particularly with the first dose, and more drug interactions via CYP2D6/CYP2C9.4·11
Pharmacokinetic detail and dose adjustment: Carvedilol undergoes extensive first-pass hepatic metabolism via CYP2D6 and CYP2C9, yielding a bioavailability of approximately 25-35%.9 The RS(+) enantiomer (which carries most of the beta-blocking activity) is metabolized primarily by CYP2D6, while the S(-) enantiomer (carrying more alpha-1 activity) is metabolized by CYP2C9. This dual CYP dependency creates two distinct drug interaction risks. CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) substantially increase carvedilol beta-blocking exposure and risk of bradycardia; CYP2C9 inhibitors (fluconazole, amiodarone) increase alpha-1 blocking exposure and risk of hypotension.9 CYP2D6 poor metabolizers have carvedilol plasma concentrations approximately two to three times higher than extensive metabolizers, with corresponding increases in HR and BP effects. Carvedilol is eliminated predominantly by hepatic metabolism; it does not require dose adjustment for renal impairment alone because renal excretion of unchanged drug is negligible.9 However, severe hepatic impairment (Child-Pugh C) is a contraindication; extensive hepatic extraction means that first-pass metabolism is severely impaired, leading to dramatically elevated plasma concentrations. Food increases carvedilol bioavailability by slowing absorption and reducing first-pass metabolism; it should be taken with food to reduce the risk of orthostatic hypotension from peak concentration effects.9
Selectivity: highly cardioselective (beta-1) with eNOS-stimulating vasodilation (beta-3 agonism and direct eNOS upregulation). ISA: none. Vasodilation: yes, via endothelial NO release. Lipid solubility: moderate. Half-life: 12-19 hours (once-daily dosing). Metabolism: hepatic (CYP2D6). Angina dosing: 5-10 mg once daily.12 Clinical advantages include NO-mediated vasodilation leading to less peripheral vasoconstriction, less erectile dysfunction (NO pathway preserved), SENIORS trial benefit in elderly HFrEF,12 and a favorable metabolic profile. The limitation is CYP2D6 dependency causing variable plasma levels between extensive and poor metabolizers.12
Pharmacokinetic detail and dose adjustment: Nebivolol is metabolized almost entirely by CYP2D6, and the pharmacokinetic consequences of CYP2D6 polymorphism are more pronounced for nebivolol than for any other commonly used beta-blocker.12 In CYP2D6 extensive metabolizers, the effective half-life is approximately 10 hours; in CYP2D6 poor metabolizers, accumulation of the parent compound extends the effective half-life to 30-50 hours.12 This disparity means that the standard 5 mg once-daily dose may produce excessive and prolonged bradycardia in poor metabolizers, and initial dosing at 2.5 mg with careful HR monitoring is advisable when CYP2D6 poor metabolizer status is suspected (clinically: unexpected over-response to usual doses, history of ADRs to other CYP2D6-metabolized drugs). CYP2D6 inhibitors, particularly fluoxetine and paroxetine, both commonly co-prescribed in the cardiovascular population for depression and anxiety, substantially increase nebivolol plasma levels.12 In these patients, switching to bisoprolol (CYP3A4-metabolized) avoids this interaction. Renal dose adjustment: in patients with eGFR below 30 mL/min/1.73m2, the initial dose should be 2.5 mg once daily with cautious uptitration, as renal impairment slows elimination of nebivolol metabolites.12 Hepatic impairment is a relative contraindication given the near-total dependence on hepatic CYP2D6 metabolism.12
Selectivity: non-selective (beta-1 and beta-2). ISA: none. Lipid solubility: high (marked CNS penetration). Half-life: 3-6 hours. Bioavailability: ~30% (extensive hepatic first-pass). Angina dosing: 40-320 mg/day in divided doses (or LA formulation once daily).9 Role today: largely supplanted by cardioselective agents for routine angina. Retained roles include angina with concurrent migraine prophylaxis, angina with hyperthyroidism, and selected HCM scenarios.9
Pharmacokinetic detail and dose adjustment: Propranolol is the most extensively studied beta-blocker pharmacokinetically and illustrates the consequences of high lipophilicity and extensive first-pass metabolism.9 Oral bioavailability averages approximately 30% but is highly variable between individuals (range 10-70%) because first-pass extraction varies with hepatic blood flow, which is itself variable and reduced by heart failure, cirrhosis, and concurrent medications.9 Propranolol metabolism involves CYP2D6 (for hydroxylation to the active 4-hydroxypropranolol) and CYP1A2 (for N-desisopropylation to inactive metabolites). CYP2D6 poor metabolizers achieve higher propranolol plasma levels, with greater beta-blockade at any given dose; CYP2D6 inhibitors (fluoxetine, paroxetine) and CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) both increase propranolol exposure and risk of bradycardia, AV block, and hypotension.9 Because propranolol is a high hepatic extraction ratio drug, its clearance is flow-dependent rather than capacity-dependent; conditions that reduce hepatic blood flow (severe heart failure, portosystemic shunting in cirrhosis) reduce clearance substantially and increase bioavailability of oral doses.9 Renal impairment does not require dose adjustment for propranolol itself, but the active metabolite 4-hydroxypropranolol is renally cleared and may accumulate in severe chronic kidney disease, contributing to additional beta-blockade.9 The high lipophilicity of propranolol enables extensive CNS penetration, explaining its efficacy in migraine prophylaxis, essential tremor, and performance anxiety, but also its higher incidence of fatigue, sleep disturbance, vivid dreams, and depressive symptoms compared with hydrophilic cardioselective agents.9
Beta-blockers are recommended as first-line agents for stable exertional angina in all patients without contraindications (ESC 2019 Class I; ACC/AHA 2012 Class I).5·6 Preferred agents include metoprolol succinate ER, bisoprolol, and carvedilol (when HFrEF or HTN coexist). Titrate every 2 weeks based on resting HR response (target 55-60 bpm), symptomatic benefit, and tolerability.5·6
Beta-blockers are the cornerstone of post-MI pharmacotherapy.1·9 Benefits beyond angina include reduced risk of sudden cardiac death (anti-arrhythmic effect via reduced sympathetic stimulation and elevated VF threshold), attenuated adverse ventricular remodeling, reduced reinfarction risk, and lower long-term mortality.1 Preferred agents post-MI include metoprolol succinate ER, carvedilol (if reduced EF), and bisoprolol. For post-MI angina specifically: continue indefinitely regardless of EF.5·6 Note on evolving evidence: the REDUCE-AMI trial (2024) suggested that in patients with preserved EF post-MI, indefinite beta-blocker therapy may not reduce major adverse cardiovascular events (MACE) compared with discontinuation; current guidelines still generally recommend continuation, particularly when angina is present.6
Beta-blockers are the only antianginal class with proven mortality benefit in HFrEF. Three evidence-based agents with mortality data are: carvedilol (COPERNICUS, US Carvedilol HF trial);4 metoprolol succinate ER (MERIT-HF);2 and bisoprolol (CIBIS-II).3 Never initiate in acute decompensation. Initiate only when the patient is euvolemic and stable. Start at the lowest dose and uptitrate slowly over weeks.2·3·4
Use cardioselective agents (bisoprolol, metoprolol succinate, nebivolol). Beta-blockers mask tachycardia and tremor of hypoglycemia; sweating is preserved (sympathetic cholinergic, not blocked by beta-blockers). Counsel patients on more frequent glucose monitoring during initiation and dose changes. Do NOT withhold if otherwise indicated post-MI or in HFrEF; benefit clearly outweighs risk.5·6
COPD without significant reversibility: cardioselective agents (bisoprolol preferred) can be used at standard doses with acceptable safety.8 GOLD guidelines do not classify cardioselective beta-blockers as contraindicated in COPD.8 Significant bronchospastic disease or active asthma: relatively contraindicated; CCBs or ivabradine are alternatives for HR reduction in this setting.8
Vasospastic (Prinzmetal) angina is a class effect contraindication: beta-2 blockade removes coronary vasodilatory tone; unopposed alpha-1-mediated vasoconstriction exacerbates or precipitates coronary spasm. This applies to ALL beta-blockers including cardioselective agents.8 Management alternative: CCBs + long-acting nitrates. High-degree AV block (2nd degree Mobitz II; 3rd degree complete heart block) without pacemaker: beta-blockade further depresses AV nodal conduction with risk of complete AV block and hemodynamic collapse.9 Sick sinus syndrome without pacemaker: risk of severe symptomatic bradycardia.9 Severe decompensated heart failure: acute initiation risks further hemodynamic deterioration; wait until euvolemic and stable.2·3 Cardiogenic shock.9
Significant bradycardia (<50 bpm at rest); symptomatic hypotension; severe peripheral arterial disease (claudication at rest; critical limb ischemia); active bronchospastic disease; pheochromocytoma without prior alpha-blockade (unopposed alpha-mediated hypertensive crisis; alpha-blocker must precede beta-blocker); cocaine-induced angina (use benzodiazepines and CCBs instead).9
Chronic beta-adrenergic receptor blockade induces receptor upregulation, an increase in the number and sensitivity of beta-adrenergic receptors on cardiac and vascular tissue. Abrupt discontinuation exposes this upregulated receptor population to normal circulating catecholamines, producing exaggerated tachycardia and hypertension, markedly increased MVO2, coronary vasospasm in susceptible individuals, increased platelet aggregability, and heightened risk of rebound angina (often more severe than pre-treatment baseline), acute MI, sudden cardiac death, and ventricular arrhythmias.9
Never abruptly discontinue beta-blockers in patients with known CAD or angina. Taper over at least 1-2 weeks by reducing the dose by 50% every 3-7 days.9 Example with metoprolol: 100 mg → 50 mg (3-7 days) → 25 mg (3-7 days) → 12.5 mg (3-7 days) → discontinue (total: 2-3 weeks). Perioperative management: continue beta-blockers through the perioperative period; if NPO, switch to IV metoprolol or esmolol infusion intraoperatively; resume oral beta-blocker as soon as tolerated postoperatively. De novo initiation less than 1 week before non-cardiac surgery: POISE trial showed increased risk of stroke with high-dose metoprolol started acutely; avoid acute high-dose perioperative initiation.13
Cardiovascular adverse effects include bradycardia (usually asymptomatic at target HR 55-60 bpm; dose reduction if symptomatic <50 bpm), AV block (monitor PR interval), and hypotension (more common with carvedilol due to alpha-1 blockade).9 Pulmonary: bronchospasm is most significant with non-selective agents; cardioselective agents cause clinically meaningful bronchospasm primarily at high doses or in severe asthma.8 Metabolic effects include impaired glycogenolysis, masking of tachycardia of hypoglycemia (sweating preserved), modest increases in triglycerides and reduction in HDL with non-selective agents (carvedilol and nebivolol have neutral or favorable metabolic profiles), and modest weight gain (~1-2 kg).9 CNS effects include fatigue and lethargy (most common reason for dose reduction or discontinuation), sleep disturbance and vivid dreams (more common with lipophilic agents, specifically propranolol and metoprolol, and less with atenolol), depression (evidence mixed but monitor in susceptible patients), erectile dysfunction (class effect; nebivolol has lower incidence due to NO pathway preservation), and cold extremities (loss of beta-2-mediated peripheral vasodilation).9·12
Metoprolol succinate ER + amlodipine is the most widely used evidence-based dual antianginal combination.5·6 The beta-blocker provides HR reduction, contractility reduction, and blunting of the DHP-CCB reflex tachycardia; amlodipine provides afterload reduction and coronary vasodilation without adding to AV conduction depression.5·6 This combination addresses three hemodynamic targets (HR, contractility, afterload) with no excessive bradycardia or AV block risk.
Combining any beta-blocker with diltiazem or verapamil produces additive and potentially life-threatening cardiac conduction and contractility depression.5·6 Both depress SA node automaticity, AV nodal conduction, and contractility through different molecular mechanisms; the combined effect is pharmacodynamic and applies regardless of which specific agents are used. This combination is CONTRAINDICATED in routine practice.5·6
When angina persists on maximally tolerated BB + CCB ± nitrate, ranolazine (late INa inhibition; no hemodynamic interaction; does not worsen bradycardia or hypotension) is the ideal add-on agent.5 Ivabradine (selective If inhibition) can be added if sinus rhythm is confirmed and resting HR remains >60 bpm despite maximal beta-blocker.5
Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-1737
doi:10.1136/bmj.318.7200.1730MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007
doi:10.1016/S0140-6736(99)04440-2CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13
doi:10.1016/S0140-6736(98)11181-9Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651-1658
doi:10.1056/NEJM200105313442201Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477
doi:10.1093/eurheartj/ehz425Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA Guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164
doi:10.1016/j.jacc.2012.07.013Bangalore S, Steg G, Deedwania P, et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349
doi:10.1001/jama.2012.12559Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;(4):CD002992
doi:10.1002/14651858.CD002992Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-1362
doi:10.1016/j.ehj.2004.06.002Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003;362(9377):7-13
doi:10.1016/S0140-6736(03)13800-7Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-1390
doi:10.1016/S0140-6736(00)04560-8Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225
doi:10.1093/eurheartj/ehi115Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). Lancet. 2008;371(9627):1839-1847
doi:10.1016/S0140-6736(08)60601-7